1Q Financial Performance & Corporate Update

Resilient Performance. Stronger Foundations. Future Growth.

30 JULY 2026

Disclaimer

This presentation may contain forward-looking statements. All statements other than statements of historical facts contained in this presentation including, without limitation, those regarding our financial position, business strategies, plans and objectives of our Group for future operations, are forward looking statements.

Such forward-looking statements (if any) involve known and unknown risks, uncertainties, contingencies and other factors which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements (if any) are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. Such forward-looking statements (if any) reflect our current view with respect to future events and are not a guarantee of future performance.

Our actual results may differ materially from the information contained in such forward-looking statements (if any) as a result of numerous external factors beyond our control.

Due to rounding, numbers presented throughout this corporate presentation may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

Subject to any applicable laws, rules, regulations and guidelines having the force of law, we expressly disclaim any obligation or undertaking to release any update or revision to any forward-looking statement contained in this presentation to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Information in this presentation shall not be taken as a recommendation, advice or an offer by DXN Holdings Bhd. ("DXN" or the "Group"), the advisers, or their affiliates, representatives, partners, directors, officers, employees, advisers or agents (collectively "The Relevant Parties") or any person to enter into any transaction or an invitation to you or any other person to undertake any potential transaction. You should conduct your own due diligence on the Group. You should make your own independent appraisal of the financial condition, creditworthiness, affairs and status of the Group as the basis of any investment decision. You should be aware that any investment activity may expose them to a risk of losing the property invested. The Relevant Parties are not liable for any investment decision you make.

WHY OWN DXN TODAY

12 Reasons Supporting Growth, Cash Returns, and Valuation Upside

Investment case: structural wellness demand + premium margins + valuation gap

Sustainable Growth

Global demand, scale, and momentum.

01.	**USD7 trillion wellness boom** Global wellness market expected to grow at approximately 8% annually, DXN is structurally positioned
02.	**+12.1%(2) local-currency growth** Commercial momentum in Peru, Bolivia and other markets.
03.	**180+ country footprint** Revenue from 6 regions; 22M+ captive consumers over 30 years.

Resilient Financials

High margins, net cash and returns.

04.	**6.4% dividend yield (1)** Above selected Malaysia peer average of ~3-4%
05.	**80.6% gross profit margin (2)** FY 2026 margin expanded +50 bps YoY despite FX headwinds.
06.	**58.6% dividend payout (2)** RM159.1M declared FY2026; >RM520M cumulative since May 2023 IPO.
07.	**ROE 20.7% / ROCE 30.4% (2)** Capital-efficient model with returns expected to build as capex is commissioned.
08.	**RM440M net cash (2)** Zero net debt; RM162M capex contracted.

Attractive Valuation

Valuation gap and earnings optionality

09.	**~8x P/E vs 20–41x peers** One of the most attractive valuations in global consumer health.
10.	**>RM500M capex pipeline** Bolivia, Peru, Morocco, Brazil and Malaysia: FY2027–28 earnings engine.
11.	**Re-rating potential** Institutional awareness building as IR programme matures.
12.	**Top Governance Score and Bursa Index Recognition** Scored the highest score, 5.0 out of 5.0 in the Governance (G) pillar of the FTSE4Good Bursa Malaysia assessment. DXN is a constituent of the FTSE4Good Bursa Malaysia Shariah Index and the Bursa Malaysia Quality 50 Shariah Index.

FYE 28/29 February; YoY = Year-on-Year; QoQ = Quarter-on-Quarter; FX = Foreign exchange; ROE = Return on Equity; ROCE = Return on Capital Employed

(1) Based on trailing 4 Quarters dividend of 2.9 sen and a share price of 45 sen on 29 May 2026

(2) As at FY26

Corporate Governance: RPT

RPT SCRUTINY LED BY INDEPENDENT BOARD OF DIRECTORS

Executive Chairman Abstained from Decision Making

Executive Chairman is fully excluded from RPT decisions, not present in the room or on the call, not consulted beforehand, not briefed until after the vote (likened to a judge with a personal stake stepping down from the bench rather than pledging impartiality

Senior Independent Director Datuk Noripah Kamso chairs the discussion, alongside independent directors who determine if benchmarking (e.g., three quotations) is sufficient and who can veto the transaction

Related Party has Zero Votes, Zero Voice and Zero Presence

The person with the greatest personal stake has zero votes, zero voice, zero presence, a verifiable mechanism, not just a disclosure

At Least 5 Board Review Meetings and 3 Independent Quotations

A single RPT can pass through **5–6 Board Audit and Board Risk Committee meetings** before clearance; benchmarking requires **at least three independent quotations, the appointment of independent advisors and valuers**, treated as genuine due diligence, not a formality

Intense Deliberation and Debate by the Board

The Board independently re-debates each transaction rather than rubber-stamping the committee's conclusion

4 Key Rigorous Review Process

1. Identification against the related-party master list
2. Independent arm's-length benchmarking
3. Formal review by Group Finance and the Board Audit Committee
4. Board approval with disclosure and ongoing monitoring

Led and Decided by Independent Directors

Board Risk Committee and Board Audit Committee, both chaired by: independent directors, Stefan Heitmann, Datuk Noripah Kamso, YM Tunku Afwida Binti Tunku A. Malek, Abraham Verghese, and Lindy, each with 30+ years in audit, risk management, and capital markets

DXN'S CUSTODIANS OF TRUST

Independent directors with over 30+ years in audit, risk management, and capital markets

BOARD AUDIT COMMITTEE ("BAC")

5 MEMBERS

Oversees financial integrity, compliance and disclosure matters relating to RPTs.

Abraham Verghese	Datuk Noripah Binti Kamso	YM Tunku Arwida Binti Tunku A. Malek	Stefan Heitmann	Ong Huey Min
Chairman	Senior INED	INED	INED	INED

BOARD RISK COMMITTEE ("BRC")

5 MEMBERS

Oversees risks, governance and other non-financial considerations relating to RPTs.

Stefan Heitmann	Datuk Noripah Binti Kamso	Abraham Verghese	Ong Huey Min
Chairman	Senior INED	INED	INED

INDEPENDENT LEADERSHIP
Chaired by Independent Directors to ensure objective deliberation and strong oversight.

RIGOROUS REVIEW
Proposals undergo a thorough review and challenge across both committees.

EXPERIENCED OVERSIGHT
Seasoned directors bring diverse expertise, judgement, and an independent perspective.

BALANCED DECISION-MAKING
Robust governance ensures decisions are in the best interest of DXN and its shareholders

IN SUMMARY

A disciplined end-to-end RPT process flow

1. Identification & Assessment		2. Compliance and Review			3. Approval	4. Monitoring
Identify	**Verify**	**Benchmark**	**Finance Review**	**BAC Review**	**Approval**	**Disclose & Monitor**
Declaration forms, Related Party master list and transaction screening.	Check related-party status and obtain required internal notification.	Independent or contemporaneous comparisons support arm's-length terms.	Group Finance Department reviews the approval form and supporting documents.	Board Audit Committee reviews RPT and draft disclosure where applicable.	Board considers the transaction and approvals required.	Register update, Bursa disclosure where required and periodic review.

The process is designed to ensure each RPT is identified, assessed on normal commercial terms, reviewed by management and the Board Audit Committee, and escalated to the Board / shareholders

DXN Delivers Resilient 1QFY27 Results PBT Up 5% to RM100.9 Million, with ROE at 17% And Dividend Yield of 6.4%

1QFY27 Highlights

DXN's manufacturing facility in Ningxia, China

STOCK INFORMATION

DXN Holdings Bhd. | BURSA: 5318 | Main Market

MARKET SNAPSHOT

Market Data as at 29 July 2026

Share Price
RM0.465

Market Cap.
RM2.32
billion

Listing
Main Market

Shariah Status
Compliant

Issued Shares
4.97
billion

Trailing 4Q P/E
8.51x
EPS of 1.2 sen as at 1QFY27

DIVIDEND PROFILE

Dividend Policy
>50% of Net Profit

Dividend Yield
6.4%
As at 29 May 2026

Quarterly Dividend Payout Ratio
51% for 1QFY26

Dividend Declared 1QFY27
RM29.8 million

Average Trading Volume (4 Weeks)
2,127,800 shares

EBITDA AND PBT MARGINS BOTH EXPANDED

Momentum building QoQ, with capital efficiency improving alongside it

1QFY27	1QFY27	As at 31 May 2026	Annualised FY27
26.8%	**RM100.9m**	**RM609.5m**	**17%**
EBITDA margin **+2.7 ppt QoQ**	PBT growth **+5.0% QoQ**	Cash on hand nearly debt-free balance sheet	Return on equity

Why the fundamentals are stronger than the headline

- Sequential margin expansion in both EBITDA and PBT, driven by disciplined cost management and lower FX losses.
- Revenue softness is a demand-timing effect from channel destocking ahead of pricing actions, not a demand problem.
- Net cash position provides full flexibility to fund the growth pipeline without dilution.
- Board continues uninterrupted quarterly dividend cadence, reflecting confidence in cash generation.

FYE 28/29 February; YoY = Year-on-Year; QoQ = Quarter-on-Quarter

EBITDA AND PBT MARGINS BOTH EXPAND QoQ



1QFY27 EBITDA margin

26.8%

▲ 2.7 ppt QoQ
(4QFY26: 24.1%)

1QFY27 PBT margin

22.8%

▲ 2.6 ppt QoQ
(4QFY26: 20.2%)

Note:

(1) QoQ PATAMI moderated as 4QFY26 benefited from an over-provision of tax in prior periods.

FYE 28/29 February; YoY = Year-on-Year; QoQ = Quarter-on-Quarter

EBITDA AND PBT MARGINS BOTH EXPAND QOQ



Lower promotional spend

Seasonal marketing activity normalised after the prior quarter's push.

Reduced FX losses

Foreign exchange loss narrowed to RM6.5m from RM10.9m in 4QFY26.

Stable cost base

Improvement in margins QoQ as operating cost base held largely flat.

FYE 28/29 February; YoY = Year-on-Year; QoQ = Quarter-on-Quarter

A BALANCE SHEET BUILT FOR RESILIENCE (AS AT 31 MAY 2026)

Substantial net cash, disciplined gearing, and strengthening operating cash generation

RM609.5m

Cash & cash equivalents
(FY26: RM617.4m)

RM188.3m

Total loans & borrowings
(FY26: RM177.5m)

RM1,447.4m

Total equity
(FY26: RM1,436.2m)

RM74.2m

Net cash from operations
(1QFY26: RM54.7m)

Balance sheet discipline in practice

- Total liabilities of RM752.5m is roughly a third of Total Assets of RM2.2b, a conservatively geared Group.
- No issuances, cancellations, repurchases or repayments of debt or equity securities during the quarter — a stable capital structure.
- No material litigation and no qualifications on the FY26 audited accounts.
- Capacity for continued reinvestment in growth without straining the balance sheet.

FYE 28/29 February; YoY = Year-on-Year; QoQ = Quarter-on-Quarter

SHAREHOLDER RETURNS STABILITY

Consistent quarterly dividend cadence continues into the new financial year

29 Apr 2026

4th interim dividend (4QFY26)

- **0.70 sen per share**
- **Totaling RM34.8m**
- **Payout ratio: 55.6%**

Paid on 29 May 2026

27 Jul 2026

1st interim dividend (1QFY27)

- **0.60 sen per share**
- **Totaling RM29.8m**
- **Payout ratio: 51.0%**

Payable on 28 Aug 2026

What this signals to investors

- Board confidence in near-term cash generation, even as growth capital investment ramps up.
- A dividend track record that management views as one of the strongest, most credible signals available to investors.

FYE 28/29 February

Business Overview

DXN's coffee plantation in Minas Gerais, Brazil

FROM FUNCTIONAL INGREDIENTS TO CONSUMER PRODUCTS

DXN leverages natural ingredients such as edible mushroom and spirulina to deliver health-focused solutions.

CORE FUNCTIONAL INGREDIENTS

Cultivate and process most of our raw materials including (but not limited to) :

Ganoderma, Spirulina, Cordyceps, Pineapple, Aloevera, Tiger milk mushroom, Noni, Roselle, Lion's male mushroom

Extract Benefits From Natural Ingredients And Develop Innovative Products

FINISHED PRODUCTS

OUTCOME: TRANSFORM IN-HOUSE CULTIVATED INGREDIENTS INTO SCALABLE CONSUMER-READY FOOD AND BEVERAGE PRODUCTS

AN EXTENSIVE PRODUCT RANGE

DXN leverages natural ingredients such as edible mushroom and spirulina to deliver health-focused solutions

702 SKUS of Health-Oriented and Wellness Consumer Products as at FY26

280
Fortified food and beverages products


Lingzhi Coffee

Cocozhi


Cordyceps Coffee

Spirudle Curry


Lemonzhi

Morinzhi

Morinzyme


Cordypine

186
Health & dietary supplements products


Reishi Gano


Ganocelium

Reishilium


Roselle

Spirulina


Cordyceps

Mycovita

In powder, tablet and capsule form

137
Personal care and cosmetics products


Ganozhi Toothpaste


Ganozhi Soap


ZhiHand Sanitizer


Ganozhi Message Oil

99
Lifestyle & Living Products


Water System

Water filter

Laundry Detergent

Upstream.

Strong Biotech Capabilities

2 RESEARCH FACILITIES IN MALAYSIA AND CHINA

In-house Research Capabilities
To optimise cultivation and manufacturing processes; develop new products; and test products for certification and compliance.

Main research facility in Malaysia is **registered with the Good Manufacturing Practices+** ("GMP+") Registered Laboratory program (GMP+ B11) of the GMP+ Feed Certification Scheme.

8 CULTIVATION FACILITIES ACROSS CHINA, INDIA, MALAYSIA AND BANGLADESH

10 PLANTATIONS ACROSS CHINA, MALAYSIA, BOLIVIA, AND BRAZIL

Midstream.

In-house Production Supporting Product Quality And Supply Reliability

14 MANUFACTURING FACILITIES ACROSS KEY REGIONS

474 SKUs PRODUCED IN-HOUSE

OUT OF 702 SKUs IN PORTFOLIO AS AT FY26 *(SKU –Stock keeping unit)*

WHY IN-HOUSE PRODUCTION MATTERS

QUALITY & SUPPLY CONTROL
In-house production enables tighter oversight across quality and supply chain execution

COST EFFICIENCY
Lower logistics costs, reduced import exposure, and access to local tax incentives

REGULATORY & CERTIFICATION READINESS
Operations aligned with local and international certifications and industry standards.

STRATEGIC MARKET PROXIMITY
Facilities located to optimise access for labour, land, and key end-markets

- ✓ FY26 Revenue **RM1.9 bil**
- ✓ **85** Sales Branches
- ✓ **21.6 million** captive consumers as of FY26

Downstream.

Malaysia Homegrown With Global Market Presence



Note:
1.Revenue breakdown based on gross revenue before consideration due/paid to customers.
2.Financial year ending 29 February

STRATEGIC PILLARS FOR SUSTAINABLE GROWTH

1. Market Expansion

Expanding in existing and new markets through captive consumer growth, sales branches and selected distribution partnerships.

2. Vertical Integration

Scaling global supply infrastructure to support product availability, quality control and margin resilience.

3. Product Innovation

Leveraging in-house R&D and manufacturing to launch a wider range of health-focused products.

4. Digital Ecosystem

Using technology platforms and digital tools to improve engagement, enrolment and operating scalability.

COMPETITIVE STRENGTHS CREATED BY THESE PILLARS

1. Proven emerging market execution

Strong local execution in high-growth regions, particularly Latin America.

2. Diversified global reach

Broad international presence supports revenue diversification and reduces single-market reliance.

3. In-house expertise

Control over R&D and manufacturing supports innovation, quality and speed-to-market.

4. Profitable growth profile

Healthy earnings, cash flow and dividend discipline support shareholder returns.

5. Scalable operating platform

Integrated systems support global transactions, performance tracking and agile decision-making.

Future Growth

ROADMAP TO FY2028 / FY2030 TARGETS

FY26 Gross Sales Of RM2,008.6M Across 6 Regions And 4 Product Segments

Value driver	Benchmark position	Mid-term target (FY28)	Long-term ambition (FY30)	How we get there
Return on equity	Industry peers: 10.1%	~10% - 12%	≥15%	RM500m capex commissioning lifts capital efficiency
Gross profit margin	DXN 3-year Average: 80.1%	Maintain ≥80%	Structural expansion via automation	BKH automation, vertical integration
Dividend payout ratio	DXN FY26 Dividend Payout Ratio: 58.6%	Maintain ≥50%	Transparent multi-year roadmap	Operating cash flow growth from new capacity
Capital structure	FY26: DXN Net Cash Position	Maintain net cash position	Self-funded with selective external financing flexibility	RM355.8m FY26 operating cash flow
Global footprint	FY26: 180+ countries, 21.6m captive consumers	Scale new markets to meaningful contribution	Top-tier global wellness platform	Disciplined market entry framework

GROWTH ROADMAP

Near-term operational milestones underpinning the next phase of growth

NOW - 6 MONTH

Bolivia
- First coffee harvest

Strategic Impact
Advancing upstream integration and raw material self-sufficiency while supporting entry into new growth markets

6–12 MONTHS

Brazil
- Coffee plantations expected first harvest

Strategic Impact
Builds capacity and supports expansion into underpenetrated markets.

12–24 MONTHS

Malaysia
- Bukit Kayu Hitam factory starts operations
- Gua Musang factory starts operations

Peru
- Chilca factory start operations

Strategic Impact
Expands manufacturing footprint and improves regional fulfilment efficiency.

24–36 MONTHS

Malaysia
- Gua Musang coffee plantation first harvest

Morocco
- Meknes factory starts operation

Bolivia
- Santa Cruz factory start operations

Strategic Impact
Deepens market reach and strengthens supply resilience.

KEY CONSUMER MARKETS

5
New Markets

- Brazil
- United Kingdom
- Argentina
- Egypt
- Chile

12
Priority Growing Markets

- Peru
- Bolivia
- Mexico
- India
- Morocco
- Turkey
- Mongolia
- Spain
- Colombia
- Ecuador
- Mauritania
- GCC

4
Emerging Opportunities

- Chad
- Bangladesh
- Hungary
- Nepal

NEXT PHASE OF GROWTH: FOOD SECURITY FOCUSED


Grape Vineyards in Bolivia


Orange Orchard in Brazil


Arabica Coffee Plantation in Brazil


Robusta Coffee Plantation in, Kelantan Malaysia


Oyster Farm in Pulau Langkawi, Malaysia


Spirulina Cultivation Farm in Kedah, Malaysia


Ganoderma Farm in Jitra, Malaysia


Lingzhi Egg from Selangor, Malaysia

LATIN AMERICA EXPANSION

Mexico | Brazil | Peru | Bolivia

Mexico

Manufacturing

Total Built-up Area:
9,725 sqm

No. of SKUs manufactured:
4

Peru

Manufacturing

Total Built-up Are
14,258 sqm

No. of SKUs to be manufactured:
29

Operation date:
Q4 2027

Brazil

Plantation

Total Land Area:
385 acres

Types of Crops:
385 acres of Arabica Coffee

Bolivia

Manufacturing

Total Built-up Are
10,163 sqm

No. of SKUs to be manufactured:
58

Operation date:
Q4 2027

Plantation

Total Land Area:
2,072 acres

Types of Crops:
111 acres of Arabica Coffee
1,942 acres of Sorghum/Soy
19 acres of Vineyard

MIDDLE EAST & NORTH AFRICA EXPANSION

Morocco | United Arab Emirates

Morocco

Manufacturing

Total Built-up Area:
7,735 sqm

Operation date:
Q1 2028

No. of SKUs to be manufac
29 (Phase 1)

United Arab Emirates

Manufacturing

Total Built-up Area:
5,219 sqm

No. of SKUs manufactured:
32

ASIA PRESENCE

India | Nepal | Bangladesh

India

Manufacturing

Total Built-up Area:
72,272 sqm (4 factories)

No. of SKUs manufactured:
151

Nepal

Manufacturing

Total Built-up Area:
396 sqm

No. of SKUs manufactured:
25

Bangladesh

Manufacturing

Total Built-up Area:
396 sqm

No. of SKUs manufactured:
4

ASIA EXPANSION

China | Indonesia | Malaysia

Malaysia

Manufacturing

Total Built-up Area:
20,552 sqm in Jitra, Kedah
No. of SKUs manufactured:
432

Total Built-up Area of Upcoming Factories:

- 40,468 sqm in Gua Musang, Kelantan **(Operational by 3Q 2027 | To Manufacture 73 SKUs)**
- 35,669 sqm in Bukit Kayu Hitam, Kedah **(Operational by 2Q 2028 | To Manufacture 118 SKUs)**

Plantation

Types of Crops:
11,605 acres of Robusta Coffee
21 acres of Durian
~10 acres of Pineapple
~2 acres of Mango Ginger
~50 acres of Sorghum and more in the pipeline

China

Manufacturing

Total Built-up Area:
23,470 sqm (2 factories)

No. of SKUs manufactured:
59

Plantation

Total Land Area:
16.5 acres of Tea

Indonesia

Manufacturing

Total Built-up Area:
1,309 sqm

No. of SKUs manufactured:
21

Group Transformation Programme

GTP CONSOLIDATES BUILT SCALE INTO DISCIPLINED EXECUTION

Four pillars turn existing infrastructure into an integrated operating platform

PILLAR 1

Vertically Integrated & Sustainable Supply Chain (VISSC)

PILLAR 2

Operational Excellence

PILLAR 3

Global Revenue Strategy

PILLAR 4

Branding & Strategic Communication

GTP ensures that we:

- ✓ Align strategy to execution
- ✓ Drive operational excellence
- ✓ Create sustainable value
- ✓ Build a future-ready DXN

GTP (Group Transformation Program) is DXN's enterprise-wide execution system that integrates and coordinates a portfolio of transformation programs across four strategic clusters.

This enables consistent execution, stronger governance and scalable value creation across the Group.

14
Manufacturing facilities

180+
Distribution markets

22.1m
Captive consumers

3
Decades of built scale

EVERY INITIATIVE IS OWNED, TRACKED AND ESCALATED BY DESIGN



Structure

Each pillar is broken into named strategic programs, and each program into projects with a single named owner, a KPI tracker, and a cost-benefit case.

Governance

A Group Transformation Program Steering Committee (GTPSC), pillar chairs, project managers and a Project Management Office (PMO) provide weekly-to-quarterly oversight, with escalation up to the Board where needed.

Execution discipline

Pillar input is consolidated into one initiative register, de-duplicated, scored on impact/effort, assigned an owner, then moved into execution. Nothing proceeds without alignment, funding, ownership and prioritisation confirmed.

Sustainability

DXN Holdings named regional social impact leader at ESG PLUS Awards 2025

RECOGNITION OF DXN'S SUSTAINABILITY COMMITMENT

Independent Recognition, Index Inclusion, And Rating Improvement Reflect DXN's Strengthening ESG Profile

ESG PLUS AWARD

☆ WINNER ☆

SOCIAL CATEGORY

Recognition of DXN's deep commitment to safeguarding the rights and well-being of its global workforce.

INDEX INCLUSION

FTSE4Good	FTSE4Good
FTSE4Good Bursa Malaysia	**FTSE4Good** Bursa Malaysia Shariah
Bursa Quality 50	**Bursa Quality 50** Shariah

✓ Indicates strong ESG governance and financial quality

ESG RATING by BURSA MALAYSIA FTSE Russell

From FYE 2024 to FYE 2025

3.0 ★★★

Percentile Rank: 49

Governance Score:	5.0
Social Score:	3.3
Environment Score:	2.5

KEY SUMMARIES

Why DXN?

- Global wellness platform with a 33-year Ganoderma moat
- 80.6% GP margin, 180+ country footprint
- 21.6M+ captive consumers
- RM617M cash and net cash

Why Now?

- FY2026 marks a year of substantial strategic investment: >RM500M committed across 6 new facilities
- Constant-currency revenue growth was +12.1%
- Entry ahead of capex commissioning is historically an attractive window for long-term investors

What Makes DXN Distinctive?

- Industry-leading EBITDA margin of 27.5%
- Fortress balance sheet
- A global footprint spanning 180+ countries
- A 30-year track record of consistent execution and shareholder returns

What Drives The Next Leg Of Growth?

- **6 manufacturing facilities** in the pipeline across the globe
- **3 new plantations** to strengthen upstream supply security
- Entry into new / underpenetrated markets, with **8 new markets launched or in pipeline**
- **Group Transformation Programme** across four strategic clusters to increase productivity

Thank You.

Appendix

BOARD OF DIRECTORS

Governance-led leadership with deep industry, finance and international experience.

Datuk Lim Siow Jin
Non-Independent Executive Chairman

66 | Male | Malaysia

Founder	Strategy	Operations

Prajith Pavithran
Executive Director & Chief Executive Officer

47 | Male | USA

Global Market Expansion	Sales Leadership	Group Strategy

Dato' Lim Boon Yee
Non-Independent Non-Executive Director

62 | Male | Malaysia

Administration	Licensing	Overseas Subsidiaries

Datuk Noripah Binti Kamso
Senior Independent Non-Executive Director

68 | Female | Malaysia

Banking	Governance	Capital Markets

YM Tunku Afwida Binti Tunku A. Malek
Independent Non-Executive Director

60 | Female | Malaysia

Finance	Risk Management	Investment

Stefan Heitmann
Independent Non-Executive Director

60 | Male | Germany

Healthcare	Operations	Regional Leadership

Abraham Verghese A/L T V Abraham
Independent Non-Executive Director

70 | Male | Malaysia

Audit	Risk	Accounting

Ong Huey Min
Independent Non-Executive Director

67 | Female | Malaysia

Audit	Tax	Governance

KEY SENIOR MANAGEMENT

Experienced leadership team driving operations, finance, technology and market execution

Prajith Pavithran
Executive Director & Chief Executive Officer

47 | Male | USA

Global Market Expansion	Sales Leadership	Group Strategy

Lim Beng Cheng
Chief Financial Officer

50 | Female | Malaysia

Finance & Governance	Financial Controls	IPO Readiness

Abdul Hafiz Mahmood Bin Hisham
Chief Operating Officer

38 | Male | Malaysia

Operations	Cross-functional Execution	Resource Optimisation

Muhammad Luthfi Hidayat
Chief Technology Officer

51 | Male | Indonesia

Technology Systems	Digital Infrastructure	Process Improvement

Saleem Shajeer
Chief Marketing Officer

48 | Male | India

International Marketing	Distributor Growth	Market Expansion